Results 141 to 150 of about 10,096 (205)

Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status. [PDF]

BMC Cancer
Wei Z, Gong B, Li X, Chen C, Zhao Q.
europepmc   +1 more source

RETRACTION: Targeting MYCN IRES in MYCN‐amplified Neuroblastoma With Mir‐375 Inhibits Tumor Growth and Sensitizes Tumor Cells to Radiation [PDF]

openalex   +1 more source

Figure S5 from Impaired Antitumor Immune Response in <i>MYCN</i>-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment

, 2023
Jamila Kacher, Olivier Manches, Caroline Aspord, Hervé Sartelet, Laurence Chaperot   +4 more
openalex   +1 more source

Supplementary Figures 1-5 from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes <i>MYCN</i>-Amplified Neuroblastoma <i>In Vivo</i>

, 2023
Amir Faisal, Lynsey Vaughan, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Sian Avery, Yann Jamin, Simon P. Robinson, Paul Workman, Julian Blagg, Florence I. Raynaud, Suzanne A. Eccles, Louis Chesler, Spiros Linardopoulos   +13 more
openalex   +3 more sources

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification. [PDF]

Cancers (Basel), 2021
Berthold F, Ernst A, Ackermann S, Bartenhagen C, Christiansen H, Hero B, Rosswog C, von Schweinitz D, Klingebiel T, Schmid I, Simon T, Fischer M.   +11 more
europepmc   +1 more source

Diphenyleneiodonium Chloride Inhibits Mycn-Amplified Neuroblastoma by Targeting Mycn Induced Mitochondrial Alteration

Soraya Epp, Stephanie Maher, Amirah Adlina Abdul Aziz, Simone Marcone, Donagh Egan, Saija Haapa-Paananen, Vidal Fey, Kristiina Iljin, Kieran Wynne, Lasse D. Jensen, Walter Kölch, Melinda Halász   +11 more
openalex   +1 more source

Retinoblastoma with MYCN Amplification Diagnosed from Cell-Free DNA in the Aqueous Humor. [PDF]

Ocul Oncol Pathol
Joseph S, Pike S, Peng CC, Brown B, Xu L, Berry JL, Chévez-Barrios P, Hubbard GB, Grossniklaus HE.   +8 more
europepmc   +1 more source

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. [PDF]

Eur J Cancer, 2020
Campbell K, Naranjo A, Hibbitts E, Gastier-Foster JM, Bagatell R, Irwin MS, Shimada H, Hogarty M, Park JR, DuBois SG.   +9 more
europepmc   +1 more source

Additional file 2 of The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

, 2022
Silvia Lampis, Salvatore Raieli, Luca Montemurro, Damiano Bartolucci, Camilla Amadesi, Sonia Bortolotti, Silvia Angelucci, Anna Lisa Scardovi, Giammario Nieddu, Lucia Cerisoli, Francesca Paganelli, Sabrina Valente, Matthias Fischer, Alberto M. Martelli, Gianandrea Pasquinelli, Andrea Pession, Patrizia Hrelia, Roberto Tonelli   +17 more
openalex   +1 more source

Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status. [PDF]

Int J Mol Sci, 2020
Currò M, Ferlazzo N, Giunta ML, Montalto AS, Russo T, Arena S, Impellizzeri P, Caccamo D, Romeo C, Ientile R.   +9 more
europepmc   +1 more source